RxDoctor Payments DataLook up a doctor →

Ahmad Munir, MD

Interventional Cardiology · Flint, MINPI 1730145228

Payments from drug & device makers

$197,561in general payments, 2019–2025

Across 592 payments — averaging $333.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$163K
  • Abbott$23K
  • Inari Medical, Inc.$4K
  • Abiomed$2K
  • Amgen$699
  • Pfizer$640
  • plus $4K from 31 others

What the payments were for

  • Speaking & faculty fees$151,00086%
  • Travel & lodging$11,0496%
  • Food & beverage$13,6078%
  • Education$310%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$197,561 in reported general payments places this provider in the 80th percentile of 187 interventional cardiology providers in Michigan.

See all interventional cardiology providers in Michigan

Medicare billing

Part B allowed, 2024
$137,845
Medicare patients
371
Services billed
1,165

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban66$91,194
BrilintaTicagrelor41$31,326
XareltoRivaroxaban26$26,232
Repatha SureclickEvolocumab13$14,178
EntrestoSacubitril/Valsartan13$11,818
ClopidogrelClopidogrel Bisulfate118$3,105
Metoprolol Succinate117$1,757
Atorvastatin Calcium89$1,343
Rosuvastatin Calcium47$1,001
Diltiazem 24hr Er (Cd)Diltiazem Hcl25$948
Isosorbide Mononitrate ErIsosorbide Mononitrate38$586
Metoprolol Tartrate88$576
Losartan Potassium63$561
Potassium Chloride20$364
Carvedilol16$312

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$640$91,19466 claims
AstraZenecaBrilinta$197$31,32641 claims
Johnson & JohnsonXarelto$274$26,23226 claims
NovartisEntresto$560$11,81813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 187 interventional cardiology providers in Michigan.

Other interventional cardiology in Flint

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →